Stocks to watch: RPRX, DDS and DSCI

During the first week of January, Repros Therapeutics Inc. ( NASDAQ: RPRX )
received Institutional Review Board (IRB) approval to commence the Phase IIb
study of Androxal in men with secondary hypogonadism. Last month, Repros
reported its plans to license its testosterone treatment by the end of 2011 and
expects to raise cash through a share sale by March 2011. Repros shares have a
52-week range of $1.11-$4.88. The stock is currently trading above its 50-day
and 200-daymoving averages. Repros shares gained 2.07% in the last three trading
sessions. The Woodlands, Texas-based Reprose is a development-stage
biopharmaceutical company, engaged in the development of oral small molecule
drugs for unmet medical needs. Dillards Inc. ( NYSE: DDS ) shares rallied on
Thursday after the company said that it form a real estate investment trust.
Last December, Dillards declared a cash dividend of $0.04 per share on the Class
A and Class B Common Stock of the Company payable February 1, 2011. Dillards
announced its plans to repurchase up to $250 million of its Class A Common Stock
through open market or through privately negotiated transactions. Dillard's is
a    Little Rock, Arkansas-based retailer, engaged in apparel and home
furnishing retail business. Derma Sciences Inc. ( NASDAQ: DSCI ), last July,
Derma Sciences submitted a 510(k) application to the U.S. Food and Drug
Administration for MEDIHONEY Gel Wound & Burn Dressing. It also announced that
the U.S. Patent and Trademark Office has issued patent No. 7,714,183 related to
the Company`s MEDIHONEY Calcium Alginate Dressing. Derma Sciences shares have a
52-week range of $4.40-$9. The stock is currently trading above its 50-day and
200-day moving averages. In the last one year, Derma shares climbed 564.47%.
Derma is a Princeton, New Jersey-based specialty medical device/pharmaceutical
company, focusing primarily on wound care. This corporate profile is provided
for information purposes only and should not be used as the basis for any
investment decision. We are neither licensed nor qualified to provide investment
advice. We were not paid, nor do we hold a position in these stocks. We reserve
the right to buy or sell any stock mentioned in this report at any time after
this post.